Neogenix Oncology® is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company’s therapeutic program is focused on developing new drugs that can improve outcomes, extend survival, and improve the overall quality of life. The goal of the diagnostic program is to develop products that will enable earlier detection, and the potential for earlier intervention. Our current Phase I clinical trials are directed toward patients with late-stage pancreatic and colorectal cancer.
One of the most important steps in the product development process is the clinical trials, in which cancer patients volunteer to receive experimental therapy and be observed for its effects.
Neogenix Oncology® posts information for all ongoing Neogenix Oncology®-sponsored trials to the National Institutes of Health's ("NIH") ClinicalTrials.gov website. To learn more about the Neogenix Oncology® clinical trials that are underway or to find out if a study is enrolling patients in your area, please click here. The institutions conducting the trials may also provide information on their web sites.
Cancer patients interested in clinical trial participation should discuss this option with their physicians. To have your name added to our e-mail list and to receive additional information, please visit and register at the following site: firstname.lastname@example.org
Neogenix Oncology® posts protocol information for all ongoing Neogenix Oncology®-sponsored trials to the National Institutes of Health's ("NIH") ClinicalTrials.gov web site
click here. To have your name added to our e-mail list and to receive additional information, please visit and register at the following site: email@example.com
More information on cancer and its management can be found at the websites of
• PANCAN (Pancreatic Cancer Action Network)
• Pancreatic Cancer Home Page at the National Cancer Institute (NCI)
• Mayo Clinic Pancreatic Cancer
• The National Comprehensive Cancer Network (NCCN)
“We are developing novel drugs not only for the treatment of cancer but to diagnose cancer earlier on in the game.”
Philip M Arlen, MD
Chief Executive Officer